Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization-Reference-Cited by-同舟云学术

Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization

Published:2018-06-28 Issue:1 Volume:18 Page:
ISSN:1471-5945
Container-title:BMC Dermatology
language:en
Short-container-title:BMC Dermatol

Author:

Armstrong April W.,Foster Shonda A.,Comer Brian S.,Lin Chen-Yen,Malatestinic William,Burge Russel,Goldblum Orin

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1186/s12895-018-0072-2.pdf

Reference23 articles.

1. Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–94.

2. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6.

3. Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, Lebwohl M. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961–7. e965

4. Edson-Heredia E, Zhu B, Lefevre C, Wang M, Barrett A, Bushe CJ, Cox A, Wu JJ, Maeda-Chubachi T. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using clinical practice research datalink. J Eur Acad Dermatol Venereol. 2015;29:955–63.

5. Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014;15:45–50.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epicardial Adipose Tissue and Psoriasis: A Systematic Review and Meta-Analysis;Journal of Clinical Medicine;2024-08-13

2. Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey;Journal of Dermatological Treatment;2024-06-24

3. Healthcare resource utilization patterns in psoriasis patients using biologic and conventional treatments in Finland;Frontiers in Immunology;2024-06-10

4. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor;Journal of Managed Care & Specialty Pharmacy;2023-12

5. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor;Journal of Managed Care & Specialty Pharmacy;2023-12